Trend Following
(11)
▼
Momentum
(6)
▼
Volatility
(5)
▼
Pattern Recognition
(5)
▼
Mean Reversion
(4)
▼
Volume Based
(5)
▼
Advanced
(10)
▼
ACXP
$1.59
$
Acurx Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, develops antibiotics to treat bacterial infections. Its lead antibiotic candidate is ibezapolstat, a novel mechanism of action that targets the polymerase IIIC enzyme that has completed Phase II clinical trial to treat patients with clostridium difficile infections. The company is also developing ACX-375C, a potential oral and parenteral treatment targeting gram-positive bacteria, including methicillin-resistant staphylococcus aureus, vancomycin-resistant enterococcus, and penicillin-resistant streptococcus pneumoniae. Acurx Pharmaceuticals, Inc. was incorporated in 2017 and is headquartered in Staten Island, New York.
Next Earnings
2026-02-25
Beta
-1.218
Average Volume
Market Cap
Last Dividend
CIK
0001736243
ISIN
US00510M2035
CUSIP
00510M203
CEO
David Luci
Sector
Healthcare
Industry
Biotechnology
Full Time Employees
4
IPO Date
2021-06-25
Status
Active
Latest News
| Title | Headline | Publisher | Date |
|---|---|---|---|
| Acurx Pharmaceuticals to Discuss Full Year and Fourth Quarter 2025 Financial Results on March 13, 2026 Conference Call and Provide Business Update | STATEN ISLAND, N.Y., Feb. 16, 2026 /PRNewswire/ -- Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) ("Acurx" or the "Company"), a late-stage biopharmaceutical company developing a new class of antibiotics for difficult-to-treat bacterial infections, announced today that the Company will discuss its full year and fourth quarter 2025 financial results on Friday, March 13, 2026 at 8:00 am ET before the U.S. financial markets open. | PRNewsWire | 2026-02-16 08:01:00 |
| USPTO Grants Acurx Pharmaceuticals New Patent for DNA Polymerase IIIC Inhibitors | STATEN ISLAND, N.Y., Feb. 2, 2026 /PRNewswire/ -- Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) ("Acurx" or the "Company"), a late-stage biopharmaceutical company developing a new class of small molecule antibiotics for difficult‑to‑treat bacterial infections, today announced that the United States Patent and Trademark Office has granted a new U.S. patent, US 12,534,470. | PRNewsWire | 2026-02-02 08:00:00 |
| Has Acurx Pharmaceuticals (ACXP) Outpaced Other Medical Stocks This Year? | Here is how Acurx Pharmaceuticals, Inc. (ACXP) and Adial Pharmaceuticals, Inc. (ADIL) have performed compared to their sector so far this year. | Zacks Investment Research | 2026-01-06 10:40:36 |
SEC Filings
| Type | Filing Date | Accepted Date | Link |
|---|---|---|---|
| EFFECT | 2026-02-11 | 2026-02-12 | View Filing |
| 424B3 | 2026-02-11 | 2026-02-11 | View Filing |
| S-1 | 2026-02-02 | 2026-02-02 | View Filing |
| EFFECT | 2026-01-06 | 2026-01-07 | View Filing |
| S-3/A | 2025-12-30 | 2025-12-30 | View Filing |
| SC 13G/A | 2025-11-14 | 2025-11-14 | View Filing |
| 10-Q | 2025-11-12 | 2025-11-12 | View Filing |
| 424B3 | 2025-11-10 | 2025-11-10 | View Filing |
| S-1 | 2025-10-20 | 2025-10-20 | View Filing |
| 8-K | 2025-09-22 | 2025-09-22 | View Filing |
| 8-K | 2025-09-19 | 2025-09-19 | View Filing |
| SC 13G | 2025-08-14 | 2025-08-14 | View Filing |
| 10-Q | 2025-08-11 | 2025-08-11 | View Filing |
| DEFA14A | 2025-08-05 | 2025-08-05 | View Filing |
| DEF 14A | 2025-08-04 | 2025-08-05 | View Filing |
| 8-K | 2025-07-31 | 2025-07-31 | View Filing |
| PRE 14A | 2025-07-24 | 2025-07-25 | View Filing |
| EFFECT | 2025-07-24 | 2025-07-24 | View Filing |
| 8-K | 2025-07-17 | 2025-07-17 | View Filing |
| S-1 | 2025-07-15 | 2025-07-14 | View Filing |
| S-3 | 2025-07-09 | 2025-07-09 | View Filing |
| D | 2025-06-27 | 2025-06-27 | View Filing |
| 8-K | 2025-06-20 | 2025-06-20 | View Filing |
| EFFECT | 2025-05-30 | 2025-05-30 | View Filing |
| 424B3 | 2025-05-29 | 2025-05-29 | View Filing |
| ARS | 2025-05-29 | 2025-05-29 | View Filing |
| DEFA14A | 2025-05-29 | 2025-05-29 | View Filing |
| DEF 14A | 2025-05-29 | 2025-05-29 | View Filing |
| S-1 | 2025-05-21 | 2025-05-21 | View Filing |
| D | 2025-05-20 | 2025-05-20 | View Filing |
| PRE 14A | 2025-05-19 | 2025-05-19 | View Filing |
| 8-K | 2025-05-13 | 2025-05-13 | View Filing |
| 10-Q | 2025-05-12 | 2025-05-12 | View Filing |
| 8-K | 2025-05-08 | 2025-05-08 | View Filing |
| EFFECT | 2025-04-15 | 2025-04-15 | View Filing |
| S-1 | 2025-04-04 | 2025-04-04 | View Filing |
| 8-K | 2025-03-28 | 2025-03-28 | View Filing |
| D | 2025-03-21 | 2025-03-20 | View Filing |
| EFFECT | 2025-03-20 | 2025-03-20 | View Filing |
| 8-K | 2025-03-18 | 2025-03-18 | View Filing |
| S-8 | 2025-03-17 | 2025-03-17 | View Filing |
| POS AM | 2025-03-17 | 2025-03-17 | View Filing |
| 10-K | 2025-03-17 | 2025-03-17 | View Filing |
| 8-K | 2025-03-10 | 2025-03-10 | View Filing |
| 424B5 | 2025-03-10 | 2025-03-10 | View Filing |
| 8-K | 2025-02-26 | 2025-02-26 | View Filing |
| EFFECT | 2025-02-07 | 2025-02-07 | View Filing |
| 4 | 2025-02-06 | 2025-02-06 | View Filing |
| 4 | 2025-02-06 | 2025-02-06 | View Filing |
| 4 | 2025-02-06 | 2025-02-06 | View Filing |
| S-1 | 2025-01-31 | 2025-01-31 | View Filing |
| D | 2025-01-17 | 2025-01-17 | View Filing |
| 4 | 2025-01-08 | 2025-01-08 | View Filing |
| 4 | 2025-01-08 | 2025-01-08 | View Filing |
| 4 | 2025-01-08 | 2025-01-08 | View Filing |
| 4 | 2025-01-08 | 2025-01-08 | View Filing |
| 4 | 2025-01-08 | 2025-01-08 | View Filing |
| 4 | 2025-01-08 | 2025-01-08 | View Filing |
| 424B5 | 2025-01-07 | 2025-01-07 | View Filing |
| 8-K | 2025-01-07 | 2025-01-07 | View Filing |
| 424B3 | 2025-01-06 | 2025-01-06 | View Filing |
| 8-K | 2024-11-13 | 2024-11-13 | View Filing |
| 10-Q | 2024-11-12 | 2024-11-12 | View Filing |
| 8-K | 2024-08-09 | 2024-08-09 | View Filing |
| 10-Q | 2024-08-08 | 2024-08-08 | View Filing |
| 4 | 2024-06-18 | 2024-06-18 | View Filing |
| 4 | 2024-06-18 | 2024-06-18 | View Filing |
| 4 | 2024-06-18 | 2024-06-18 | View Filing |
| 4 | 2024-06-18 | 2024-06-18 | View Filing |
| 4 | 2024-06-18 | 2024-06-18 | View Filing |
| 8-K | 2024-06-17 | 2024-06-17 | View Filing |
| 8-K | 2024-05-15 | 2024-05-15 | View Filing |
| 10-Q | 2024-05-14 | 2024-05-14 | View Filing |
| ARS | 2024-04-29 | 2024-04-29 | View Filing |
| DEFA14A | 2024-04-29 | 2024-04-29 | View Filing |
| DEF 14A | 2024-04-29 | 2024-04-29 | View Filing |
| RW | 2024-04-17 | 2024-04-17 | View Filing |
| 4 | 2024-04-03 | 2024-04-03 | View Filing |
| 4 | 2024-04-03 | 2024-04-03 | View Filing |
| 4 | 2024-04-03 | 2024-04-03 | View Filing |
| FWP | 2024-04-02 | 2024-04-02 | View Filing |
| S-1/A | 2024-03-29 | 2024-03-29 | View Filing |
| 8-K | 2024-03-18 | 2024-03-18 | View Filing |
| S-1 | 2024-03-18 | 2024-03-18 | View Filing |
| S-8 | 2024-03-15 | 2024-03-15 | View Filing |
| 10-K | 2024-03-15 | 2024-03-15 | View Filing |
Algorithm Performance
Upgrade To Premium for Full Access
| Algorithm | Profit/Loss | Profit Factor | # Trades | Sharpe | Sortino | Efficiency |
|---|---|---|---|---|---|---|
| Volume Weighted Momentum Strategy | 27.12% | 0.9 | 7 | 0.07 | 0.29 | 50.8 |
| Fractal Pattern | 12.33% | 0.99 | 72 | 0.02 | 0.04 | 36.01 |
| Genetic Strat | 9.46% | 1.01 | 778 | 0 | 0.01 | 33.13 |
| xxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | xxx | x | xxxx | xxxxx |
| xxxxxxxxx | xxxxxxx% | x | xxx | x | xxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx | x% | x | xxx | x | x | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xxx | x | x | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xxx | xxxxx | x | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xxx | xxxxx | x | xxxxx |
| xxxxxxxxxxxxxx | xxxxxxxx% | x | xxx | x | x | xxxxx |
| xxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxxx |
| xxx | xxxxxxxx% | x | xxx | xxxxx | xxxxx | xx |
| xxxxxxxxx | xxxxxxxx% | x | xxx | xxxxx | xxxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xxx | xxxxx | xxxxx | xxxxx |
| xxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxxx |
| xxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xxx | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxx | xxxxxxxx% | xxxx | x | xxxxx | xxxxx | xxxx |
| xxxx | xxxxxx% | x | xxx | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xxx | xxxxx | xxxxx | xxxx |
| xxxxxxxxx | xxxxxxxx% | xxxx | xxx | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xxx | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | x | xxx | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xxx | xxxxx | xxxxx | xxx |
| xxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | x | xxx | xxxxx | xxxxx | xxxx |
| xxxxxxxxxx | xxxxxxxx% | xxxx | xxx | xxxxx | xxxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xxx | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xxx | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | x | xxx | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxxx |
| xxxxxxxxxxxx | xxxxxxxx% | xxxx | xxx | xxxxx | xxxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | x | xxx | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xxx | xxxxx | xxxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xxx | xxxxx | xxxxx | xxxxx |
| xxxxxxxxxx | xxxxxx% | x | xxx | xxxxx | xxxxx | xxxxx |
| xxxx | xxxxxxxx% | xxxx | xxx | xxxxx | xxxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xxx | xxxxx | xxxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xxx | xxxxx | xxxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xxx | xxxxx | xxxxx | xxxxx |